Hypoxia-Inducible Factors
From Proteopedia
| Line 35: | Line 35: | ||
Both HIF-α and β subunits are constitutively and ubiquitously expressed in almost every single cell, although some isoforms may be predominant in some specific tissues. For example, HIF-2α is mostly expressed in the endothelium, kidney, lung, heart and small intestine . While HIF-β protein levels in the cell are constant, HIF-α has a short half-life (~ 5 mins) and is highly regulated by oxygen through its ODDD domain. With normal oxygen levels (normoxia), HIF-α protein levels are rapidly degraded, resulting in essentially no detectable HIF-α protein. However, in hypoxic conditions HIF-α becomes stabilized and is translocated from the cytoplasm to the nucleus, where it dimerizes with HIF-β and the HIF complex formed becomes transcriptionally active. More than 100 genes with varying functions have been described to be transcribed by the action of HIF. Moreover, HIF regulates up to 2% of all human genes in arterial endothelial cells, either directly or indirectly . In response to hypoxia, the capacity of red blood cells to transport oxygen is upregulated by the expression of genes like ''EPO'', essential in [https://en.wikipedia.org/wiki/Erythropoiesis erythropoiesis], and genes involved in iron metabolism. In addition, a large number of genes involved in different steps of [https://en.wikipedia.org/wiki/Angiogenesis angiogenesis] have been shown to increase by hypoxia challenge, being the [[Vascular Endothelial Growth Factor | '''Vascular Endothelial Growth Factor''']] ('''VEGF''') among them. VEGF directly recruits endothelial cells into hypoxic areas to generate new blood vessels by stimulating their proliferation. Furthermore, HIF complexes have been shown to induce pro-survival factors such as [[Insulin-like growth factor | '''Insulin-like Growth Factor-2''']] ('''IGF2''') and [https://en.wikipedia.org/wiki/TGF_alpha '''Transforming Growth Factor-α'''] ('''TGF-α'''), which in turn enhances expression of HIFα itself. | Both HIF-α and β subunits are constitutively and ubiquitously expressed in almost every single cell, although some isoforms may be predominant in some specific tissues. For example, HIF-2α is mostly expressed in the endothelium, kidney, lung, heart and small intestine . While HIF-β protein levels in the cell are constant, HIF-α has a short half-life (~ 5 mins) and is highly regulated by oxygen through its ODDD domain. With normal oxygen levels (normoxia), HIF-α protein levels are rapidly degraded, resulting in essentially no detectable HIF-α protein. However, in hypoxic conditions HIF-α becomes stabilized and is translocated from the cytoplasm to the nucleus, where it dimerizes with HIF-β and the HIF complex formed becomes transcriptionally active. More than 100 genes with varying functions have been described to be transcribed by the action of HIF. Moreover, HIF regulates up to 2% of all human genes in arterial endothelial cells, either directly or indirectly . In response to hypoxia, the capacity of red blood cells to transport oxygen is upregulated by the expression of genes like ''EPO'', essential in [https://en.wikipedia.org/wiki/Erythropoiesis erythropoiesis], and genes involved in iron metabolism. In addition, a large number of genes involved in different steps of [https://en.wikipedia.org/wiki/Angiogenesis angiogenesis] have been shown to increase by hypoxia challenge, being the [[Vascular Endothelial Growth Factor | '''Vascular Endothelial Growth Factor''']] ('''VEGF''') among them. VEGF directly recruits endothelial cells into hypoxic areas to generate new blood vessels by stimulating their proliferation. Furthermore, HIF complexes have been shown to induce pro-survival factors such as [[Insulin-like growth factor | '''Insulin-like Growth Factor-2''']] ('''IGF2''') and [https://en.wikipedia.org/wiki/TGF_alpha '''Transforming Growth Factor-α'''] ('''TGF-α'''), which in turn enhances expression of HIFα itself. | ||
| - | Regulation of HIF-α subunits is achieved by pos-translational modifications such as hydroxylation, ubiquitination, acetylation and phosphorylation. De novo synthesized cytoplasmic HIF-α is rapidly hydroxylated on ''' | + | Regulation of HIF-α subunits is achieved by pos-translational modifications such as hydroxylation, ubiquitination, acetylation and phosphorylation. De novo synthesized cytoplasmic HIF-α is rapidly hydroxylated on '''Pro402''' and '''Pro564''' (in HIF-1α) or '''Pro405''' and '''Pro530''' (in HIF-2α) by a family of [[Prolyl hydroxylase domain | '''Prolyl Hydroxylases''']] ('''PHD''') that recognize the [https://en.wikipedia.org/wiki/Consensus_sequence consensus sequence] '''LXXLAP''' . These PHD require an oxygen molecule that will be splitted to catalyze the hydroxylation of the target prolines. Once the two proline residues of HIF-α are converted to hydroxyproline, the [https://en.wikipedia.org/wiki/Von_Hippel%E2%80%93Lindau_tumor_suppressor Von Hippel-Lindau tumor suppressor] (pVHL) will recognize it. pVHL acts as the substrate recognition component of a complex with E3 ubiquitin ligase activity that will then polyubiquitinate HIF-1α on Lysine 532 for '''proteasomal degradation'''. In hypoxic conditions, PHDs will be inactive due to the lack of oxygen, so HIF-α can escape proteasomal degradation and translocate to the nucleus to active gene expression. Additional modifications can also modulate HIF-α properties: acetylation of '''Lys532''' by [https://en.wikipedia.org/wiki/N-alpha-acetyltransferase_10 '''Arrest-Defective-1'''] ('''ARD1''') favors the interaction of HIF-1α with pVHL; hydroxylation of '''Asn803''' or '''851''' within the C-CAD domain (in HIF-1α or HIF-2α, respectively) by [[Factor inhibiting HIF | '''Factor Inhibiting HIF-1''']] ('''FIH-1''') prevents interaction with [https://en.wikipedia.org/wiki/P300-CBP_coactivator_family p300/CBP], thus inhibiting transcription. Furthermore, [[Mitogen-activated protein kinase | '''Mitogen-Activated Protein Kinase''']] ('''MAPK''') pathway seems to be able to phosphorylate HIF-α in response to growth factors. This phosphorylation would increase HIF complex transcriptional activity rather than affecting its stability or DNA-binding ability. |
==Clinical Significance== | ==Clinical Significance== | ||
Revision as of 14:34, 14 November 2020
|
Hypoxia-inducible factors (HIFs) are transcription factors responsible of the cellular adaptation to hypoxia, which is a condition of low oxygen availability. Among the genes regulated by HIF, we can find those involved in erythropoiesis, angiogenesis and metabolism.
Contents |
Structure
HIFs were discovered more than 30 years ago thanks to the Erythropoietin (EPO) gene, an hormone that is transcribed in hypoxic conditions and stimulates erythrocyte proliferation. EPO presents an upstream Hypoxia Response Element (HRE) that resulted to be bound by HIF. HIFs form part of the basic helix-loop-helix-Per-ARNT-Sim (bHLH-PAS) family of proteins. Active HIFs are achieved by heterodimerization of a constitutively expressed subunit HIF-β and an oxygen-regulated subunit, which can be HIF-1α or its paralogs HIF-2α and HIF-3α (Table 1.). HIF-β is also known as the aryl hydrocarbon nuclear translocator (ARNT). Their structure can contain the following domains from the N-terminus to the C-terminus:
- basic Helix-Loop-Helix (bHLH): essential for heterodimer formation and DNA binding to HRE
- Per-Arnt-Sim (PAS): their surface forms the key core of the heterodimer.
- Oxygen-dependent degradation domain (ODDD): mediates oxygen-regulated stability in the α subunits. This domain contains two Proline residues susceptible of hydroxylation and one Lysine that can be acetylated
- N-terminal and C-terminal transactivating domains (N-TAD and C-TAD): bind different coactivators to promote gene expression, such as p300/CBP.
| Member | Gene | Protein |
|---|---|---|
| HIF-1α | HIF1A | hypoxia-inducible factor 1, α subunit |
| HIF-2α | EPAS1 | endothelial PAS domain protein 1 |
| HIF-3α | HIF3A | hypoxia-inducible factor 3, α subunit |
| HIF-1β | ARNT | aryl hydrocarbon receptor nuclear translocator |
| HIF-2β | ARNT2 | aryl hydrocarbon receptor nuclear translocator 2 |
| HIF-3β | ARNT3 | aryl hydrocarbon receptor nuclear translocator 3 |
Physiological Function
Both HIF-α and β subunits are constitutively and ubiquitously expressed in almost every single cell, although some isoforms may be predominant in some specific tissues. For example, HIF-2α is mostly expressed in the endothelium, kidney, lung, heart and small intestine . While HIF-β protein levels in the cell are constant, HIF-α has a short half-life (~ 5 mins) and is highly regulated by oxygen through its ODDD domain. With normal oxygen levels (normoxia), HIF-α protein levels are rapidly degraded, resulting in essentially no detectable HIF-α protein. However, in hypoxic conditions HIF-α becomes stabilized and is translocated from the cytoplasm to the nucleus, where it dimerizes with HIF-β and the HIF complex formed becomes transcriptionally active. More than 100 genes with varying functions have been described to be transcribed by the action of HIF. Moreover, HIF regulates up to 2% of all human genes in arterial endothelial cells, either directly or indirectly . In response to hypoxia, the capacity of red blood cells to transport oxygen is upregulated by the expression of genes like EPO, essential in erythropoiesis, and genes involved in iron metabolism. In addition, a large number of genes involved in different steps of angiogenesis have been shown to increase by hypoxia challenge, being the Vascular Endothelial Growth Factor (VEGF) among them. VEGF directly recruits endothelial cells into hypoxic areas to generate new blood vessels by stimulating their proliferation. Furthermore, HIF complexes have been shown to induce pro-survival factors such as Insulin-like Growth Factor-2 (IGF2) and Transforming Growth Factor-α (TGF-α), which in turn enhances expression of HIFα itself.
Regulation of HIF-α subunits is achieved by pos-translational modifications such as hydroxylation, ubiquitination, acetylation and phosphorylation. De novo synthesized cytoplasmic HIF-α is rapidly hydroxylated on Pro402 and Pro564 (in HIF-1α) or Pro405 and Pro530 (in HIF-2α) by a family of Prolyl Hydroxylases (PHD) that recognize the consensus sequence LXXLAP . These PHD require an oxygen molecule that will be splitted to catalyze the hydroxylation of the target prolines. Once the two proline residues of HIF-α are converted to hydroxyproline, the Von Hippel-Lindau tumor suppressor (pVHL) will recognize it. pVHL acts as the substrate recognition component of a complex with E3 ubiquitin ligase activity that will then polyubiquitinate HIF-1α on Lysine 532 for proteasomal degradation. In hypoxic conditions, PHDs will be inactive due to the lack of oxygen, so HIF-α can escape proteasomal degradation and translocate to the nucleus to active gene expression. Additional modifications can also modulate HIF-α properties: acetylation of Lys532 by Arrest-Defective-1 (ARD1) favors the interaction of HIF-1α with pVHL; hydroxylation of Asn803 or 851 within the C-CAD domain (in HIF-1α or HIF-2α, respectively) by Factor Inhibiting HIF-1 (FIH-1) prevents interaction with p300/CBP, thus inhibiting transcription. Furthermore, Mitogen-Activated Protein Kinase (MAPK) pathway seems to be able to phosphorylate HIF-α in response to growth factors. This phosphorylation would increase HIF complex transcriptional activity rather than affecting its stability or DNA-binding ability.
Clinical Significance
Your Heading Here (maybe something like 'Structure')
This is a default text for your page Gonzalo Garcia-Martin/Sandbox1. Click above on edit this page to modify. Be careful with the < and > signs. You may include any references to papers as in: the use of JSmol in Proteopedia [1] or to the article describing Jmol [2] to the rescue.
Function
Disease
Relevance
Structural highlights
This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
</StructureSection>
References
- ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
- ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
Proteopedia Page Contributors and Editors (what is this?)
Gonzalo Garcia-Martin, Michal Harel, Carmen Paredes Yubero, Rocío Moreno
